Chang Jiang Shang Bao·2025-05-28 23:47Core Viewpoint - The company intends to enhance its market position through the acquisition of Zhejiang Huato Medicine Group Co., Ltd. by its wholly-owned subsidiary, Zhejiang Yinte Pharmaceutical Co., Ltd. [2][4] Group 1: Acquisition Details - Zhejiang Yinte Pharmaceutical plans to participate in the auction for 100% equity of Huato Medicine with a starting price of 369 million yuan [2][4] - Huato Medicine is a wholly-owned subsidiary of Zhejiang Nongfu Co., Ltd., which aims to focus on its core agricultural services by selling the pharmaceutical unit [2][6] - The transaction is expected to improve the company's bargaining power with suppliers and influence over end consumers in the Zhejiang market [2][7] Group 2: Financial Performance - In 2024, the company reported a revenue of 33.352 billion yuan, a year-on-year increase of 4.05%, and a net profit of 526 million yuan, up 7.53% [2][8] - The net profit after deducting non-recurring items was 510 million yuan, reflecting a significant growth of 25.74% [2][8] - The pharmaceutical wholesale segment generated 29.933 billion yuan in revenue, a 2.9% increase, while the retail segment achieved 3.178 billion yuan, growing by 15.46% [9] Group 3: Strategic Importance of Huato Medicine - Huato Medicine has a strong presence in the grassroots public medical market, and its retail chain is among the top 100 in the pharmaceutical retail sector [7] - The acquisition aligns with the company's strategic planning and business development needs, facilitating high-quality growth [7] - The transaction is also seen as a response to recent industry policy adjustments and market consolidation trends [6][7]